PHASQ stock plunges 99.00% to $0.000001 on PNK 17 Feb 2026: What traders should watch

PHASQ stock dropped -99.00% to $0.000001 on the PNK exchange during market hours on 17 Feb 2026, making it one of the session’s top losers. Volume was 2,500.00 shares versus a 50-day average of 22,310.00, signaling thin trading and extreme volatility for PhaseBio Pharmaceuticals, Inc. (PHASQ). The move follows continued Chapter 11 restructuring risk and limited liquidity in the United States OTC market. Traders should treat intraday quotes as highly unstable and weigh clinical and corporate news before positioning.

PHASQ stock price action and market context

PHASQ stock fell -99.00% to $0.000001 on PNK during market hours on 17 Feb 2026, a collapse from the previous close of $0.000100. The day’s range was narrow at $0.000001 to $0.000001, reflecting one-price prints and very low liquidity. Average volume (50-day) of 22,310.00 contrasts with today’s 2,500.00, underscoring outsized percentage moves driven by small trade sizes rather than broad selling pressure.

PHASQ stock catalysts and news drivers

PhaseBio Pharmaceuticals, Inc. (PHASQ) remains a clinical-stage biotech focused on cardiovascular assets, including bentracimab (PB2452) and PB1046. Legacy Chapter 11 restructuring and limited public float have been recurring negative catalysts since the October 2022 filing. Absent new positive clinical data or a financing update, the stock is vulnerable to headline-driven spikes and steep intraday losses.

PHASQ stock financials, metrics and valuation

PHASQ’s latest reported EPS is -2.14 and price averages show extreme depreciation: 50-day average $0.000236 and 200-day average $0.000666. Key ratios show cash per share 1.42, book value per share -3.16, and current ratio 1.75, reflecting balance-sheet stress and negative operating cash flow per share -1.61. Valuation metrics are not meaningful for trading-grade decisions because market cap reads as 0 and enterprise value is distorted by restructuring.

PHASQ stock technicals, liquidity and trading risks

Technically, trading prints are unreliable: the day low and high were both $0.000001 and relVolume is 0.11, indicating below-average participation. Bid-ask gaps and OTC market mechanics can create phantom price collapses. Short-term traders face outsized slippage risk and potential quote errors; margin or options strategies are not appropriate given liquidity and exchange (PNK) constraints.

Meyka grade and PHASQ stock forecast

Meyka AI rates PHASQ with a score of 62.73 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month indicative price of $0.00010 versus the current $0.000001, implying an implied upside of 9,900.00%. Forecasts are model-based projections and not guarantees; they assume improved liquidity or corporate action, which is speculative.

PHASQ stock risks and opportunity checklist

Primary risks for PhaseBio (PHASQ) include continued restructuring outcomes, clinical trial setbacks for PB2452, and persistent low liquidity on PNK. Potential opportunities would require a clear financing plan, successful Phase III readouts, or a restructuring resolution that restores tradable float. Investors should monitor company releases, regulatory milestones, and OTC liquidity before considering exposure.

Final Thoughts

PHASQ stock’s -99.00% intraday fall to $0.000001 on PNK on 17 Feb 2026 highlights the twin risks of restructuring legacy liabilities and razor-thin liquidity in the United States OTC market. Our review shows negative operating cash flow per share -1.61, EPS -2.14, and distorted valuation metrics that make standard ratios unreliable. Meyka AI’s model projects a 12-month indicative target of $0.00010, implying an upside of 9,900.00% from the current quote; that projection assumes meaningful corporate or clinical catalysts. Given the Grade B hold rating from Meyka AI and the company’s Chapter 11 history, traders should use strict position sizing, expect wide spreads, and treat PHASQ as speculative. For live filings and corporate updates consult the company site and official channels before trading PhaseBio website and corporate social updates on PhaseBio Twitter. Meyka AI is an AI-powered market analysis platform and this overview is informational, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.